July 13, 2024

Allergic Conjunctivitis Market Analysis

 

The allergic conjunctivitis market is projected to grow from US$1.96 billion in 2023 to US$2.40 billion by 2032, with a compound annual growth rate (CAGR) of 2.27% expected from 2024 to 2032.

 

Allergic conjunctivitis, a prevalent immunological hypersensitivity disorder known as ocular allergy (OA), is a global health concern. Its increasing frequency worldwide has led to symptoms such as itching, redness, and swelling, significantly affecting individuals’ quality of life. Despite its widespread occurrence, allergic conjunctivitis is often underdiagnosed and undertreated, with many individuals relying on over-the-counter medications and non-pharmacological remedies. This underscores the need for greater awareness and understanding of this condition for appropriate diagnosis and management.

 

 

Request a free sample copy of the report: https://www.renub.com/allergic-conjunctivitis-market-p.php

 

 

Key Drivers of the Allergic Conjunctivitis Market

 

Rising prevalence of allergic conjunctivitis worldwide: Conjunctivitis, commonly known as pink eye, can usually be diagnosed without diagnostic tests. Allergic conjunctivitis is anticipated to drive market growth in the coming years. According to an NIH article from February 2021, viral and bacterial conjunctivitis are the two primary forms of infectious conjunctivitis. Viral infection is responsible for most acute conjunctivitis cases, while bacterial infection accounts for a significant percentage of cases in children. The article also highlights the high prevalence of conjunctivitis in countries such as China. Additionally, a BMC article from March 2022 states that mainland China experiences an average annual incidence of 3.58 cases of hemorrhagic conjunctivitis per 100,000 people, indicating a rise in demand for conjunctivitis treatment and subsequent market growth.

 

Growing Awareness and Diagnosis: Enhanced awareness among healthcare professionals and patients regarding symptoms and diagnosis of allergic conjunctivitis plays a crucial role in early intervention and treatment adoption. Healthcare providers are increasingly educated about recognizing allergic conjunctivitis symptoms, such as itching, redness, and watery eyes, which facilitates timely diagnosis. This proactive approach leads to quicker initiation of appropriate treatments, including antihistamines, mast cell stabilizers, and immunotherapy, thereby improving patient outcomes. Simultaneously, patients are more informed about seeking medical advice when experiencing symptoms, which reduces delays in treatment and enhances overall management of the condition. As awareness grows, the demand for effective therapies and management strategies increases, driving the market growth for allergic conjunctivitis treatments and supporting advancements in care.

 

Growing exposure to pollutants and chemicals causes allergic conjunctivitis: Exposure to pollutants and chemicals can lead to the development of allergic conjunctivitis. The delicate membranes lining the eyelids’ inner surface and the eye’s outer surface, collectively known as the conjunctiva, can become inflamed when exposed to irritants like air pollution, industrial chemicals, and other environmental toxins. Allergic conjunctivitis is characterized by symptoms such as redness, itching, watering of the eyes, and a gritty sensation. Prolonged or repeated exposure to these pollutants can exacerbate the condition, making it essential to limit exposure wherever possible. Individuals prone to allergic reactions may benefit from using eye protection, such as glasses or goggles, and employing measures to reduce their exposure to airborne pollutants and chemicals.

 

 

North American allergic conjunctivitis market

 

The market for conjunctivitis treatment is expected to dominate North America due to the easy availability of effective treatment products and high consumer awareness. In the United States, conjunctivitis affects over 6 million people annually, with an estimated cost of millions of dollars per year. Seasonal or perennial allergic conjunctivitis is the most prevalent form of allergic conjunctivitis in the US, affecting between 15% and 40% of the population. The prevalence of conjunctivitis in Canada, where an estimated 21% of Canadians have dry eyes, is also expected to contribute to market growth.

 

Allergic Conjunctivitis Industry Analysis

 

The Allergic conjunctivitis competitive landscape includes an analysis of global and local companies which hold market shares and are well known, including Ajanta Pharma Limited, Akorn Operating Company LLC, Alembic Pharmaceutical Ltd., Cipla Inc., Indoco Remedies Ltd., Johnson & Johnson, Novartis AG, Ocular Therapeutix, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

 

 

Disease Types – Global Allergic Conjunctivitis Market is divided into 2 viewpoints

 

  1. Seasonal ALLERGIC Conjunctivitis (SAC)
  2. Perennial Allergic Conjunctivitis (PAC)

 

Drugs Class – Global Allergic Conjunctivitis Market is divided into 3 viewpoints

 

  1. Antihistamines & Mast Cell Stabilizers
  2. Corticosteroids
  3. Others

 

Distribution Channels – Global Allergic Conjunctivitis Market is divided into 4 viewpoints

 

  1. Hospital Pharmacies
  2. Online Pharmacies
  3. Retail Pharmacies & Drug Stores
  4. Others

 

Countries – Market is divided into 25 country Allergic Conjunctivitis Industry

 

 

North America

 

  1. United States
  2. Canada

 

Europe

 

  1. France
  2. Germany
  3. Italy
  4. Spain
  5. United Kingdom
  6. Belgium
  7. Netherlands
  8. Turkey

 

Asia Pacific

 

  1. China
  2. Japan
  3. India
  4. Australia
  5. South Korea
  6. Thailand
  7. Malaysia
  8. Indonesia
  9. New Zealand

 

Latin America

 

  1. Brazil
  2. Mexico
  3. Argentina

 

Middle East & Africa

 

  1. South Africa
  2. Saudi Arabia
  3. United Arab Emirates

 

 

Company Insights:

 

  1. Overview
  2. Operating business segments
  3. Product portfolio & Product Launch in Last 1 Year
  4. Recent Developments
  5. Revenue

 

Companies Covered:

Ajanta Pharma Limited

Akorn Operating Company LLC

Alembic Pharmaceutical Ltd.

Cipla Inc.

Indoco Remedies Ltd.

Johnson & Johnson

Novartis AG

Ocular Therapeutix, Inc.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

 

 

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

 

Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Website: https://www.renub.com/

Leave a Reply

Your email address will not be published. Required fields are marked *